Antagonism of cytotoxic T-lymphocyte activation by soluble CD8
暂无分享,去创建一个
G. Gao | J. Bell | D. Price | R. Phillips | A. Sewell | U. Gerth | M. Purbhoo | J. Boulter | B. Jakobsen | D. Price | G. Gao | R. Phillips
[1] Ellis L. Reinherz,et al. The differentiation and function of human T lymphocytes , 1980, Cell.
[2] P. Doherty. T cells and viral infections. , 1985, British medical bulletin.
[3] Effector Mechanisms in Allograft Rejection , 1986 .
[4] 受體(Receptor)醫學 , 1987 .
[5] C. Bieberich,et al. Role of the major histocompatibility complex class I antigens in tumor growth and metastasis. , 1988, Annual review of immunology.
[6] P. Parham,et al. Cell-cell adhesion mediated by CD8 and MHC class I molecules , 1988, Nature.
[7] Plasma levels of soluble CD8 antigen and interleukin-2 receptor antigen in patients with hairy cell leukemia, relationship with splenectomy and with clinical response to therapy. , 1989, Leukemia.
[8] A. Townsend,et al. Antigen recognition by class I-restricted T lymphocytes. , 1989, Annual review of immunology.
[9] P. Kavathas,et al. A secreted form of the human lymphocyte cell surface molecule CD8 arises from alternative splicing. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[10] R. Zambello,et al. Increased levels of soluble CD8 molecule in the serum of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related disorders. , 1989, Clinical immunology and immunopathology.
[11] C. Zielinski,et al. Soluble interleukin-2 receptor and soluble CD8 antigen in active rheumatoid arthritis. , 1990, Clinical immunology and immunopathology.
[12] R. Perlmutter,et al. Interaction of the unique N-terminal region of tyrosine kinase p56 lck with cytoplasmic domains of CD4 and CD8 is mediated by cysteine motifs , 1990, Cell.
[13] A. O'Rourke,et al. Activated CD8 binding to class I protein mediated by the T-cell receptor results in signalling , 1990, Nature.
[14] P. Parham,et al. A binding site for the T-cell co-receptor CD8 on the alpha 3 domain of HLA-A2. , 1990, Nature.
[15] P. Parham,et al. A binding site for the T-cell co-receptor CD8 on the α3 domain of HLA-A2 , 1990, Nature.
[16] T. Potter,et al. Recognition by CD8 on cytotoxic T lymphocytes is ablated by several substitutions in the class I alpha 3 domain: CD8 and the T-cell receptor recognize the same class I molecule. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[17] T. Mak,et al. CD8 is needed for development of cytotoxic T cells but not helper T cells. , 1991, Cell.
[18] T. Mak,et al. CD8 is needed for development of cytotoxic T but not helper T cells , 1991, Cell.
[19] A. Reder,et al. Soluble CD8 levels in the CSF and serum of patients with multiple sclerosis , 1991, Neurology.
[20] P. Parham,et al. CD8 independence and specificity of cytotoxic T lymphocytes restricted by HLA-Aw68. 1 , 1991, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[21] Phosphorylation of murine CD8α is not essential for responses of T cell hybridomas to antigen , 1991 .
[22] R. Perlmutter,et al. Participation of CD4 coreceptor molecules in T-cell repertoire selection , 1991, Nature.
[23] N. Shastri,et al. Requirement for association of p56 lck with CD4 in antigen-specific signal transduction in T cells , 1991, Cell.
[24] Phosphorylation of murine CD8 alpha is not essential for responses of T cell hybridomas to antigen. , 1991, International immunology.
[25] H. Grey,et al. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor , 1992, Cell.
[26] S. Cobbold,et al. Reprogramming the Immune System for Peripheral Tolerance with CD4 and CD8 Monoclonal Antibodies , 1992, Immunological reviews.
[27] R. Perlmutter,et al. Disruption of CD8‐dependent negative and positive selection of thymocytes is correlated with a decreased association between CD8 and the protein tyrosine kinase, p56lck , 1992, European journal of immunology.
[28] A. O'Rourke,et al. Cytotoxic T-lymphocyte activation involves a cascade of signalling and adhesion events , 1992, Nature.
[29] D. Littman,et al. Requirement for CD8-major histocompatibility complex class I interaction in positive and negative selection of developing T cells , 1992, The Journal of experimental medicine.
[30] H. Pircher,et al. CD8 is needed for positive selection but differentially required for negative selection of T cells during thymic ontogeny , 1993, European journal of immunology.
[31] W. Fung-Leung,et al. Thymic selection of cytotoxic T cells independent of CD8 alpha-Lck association. , 1993, Science.
[32] M. Bevan,et al. Clone-specific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells , 1993, The Journal of experimental medicine.
[33] R. Zamoyska,et al. Is CD8 dependence a true reflection of TCR affinity for antigen? , 1993, International immunology.
[34] Sarah Rowland-Jones,et al. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants , 1994, Nature.
[35] R. Zinkernagel,et al. Promethean viruses? , 1994, Nature.
[36] Zinkernagel Rm,et al. Immunology - Promethean Viruses , 1994 .
[37] R. Zamoyska,et al. The CD8 coreceptor revisited: one chain good, two chains better. , 1994, Immunity.
[38] J. Klinenberg,et al. Elevated in vivo and in vitro secretion of CD8-alpha molecules in patients with systemic lupus erythematosus. , 1994, Journal of immunology.
[39] C. Janeway,et al. Both high and low avidity antibodies to the T cell receptor can have agonist or antagonist activity. , 1994, Immunity.
[40] A. Sette,et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells , 1994, Nature.
[41] P. Romero,et al. CD8 modulation of T-cell antigen receptor–ligand interactions on living cytotoxic T lymphocytes , 1995, Nature.
[42] A. Kleinfeld,et al. T cell receptor and CD8‐dependent tyrosine phosphorylation events in cytotoxic T lymphocytes: activation of p56lck by CD8 binding to class I protein , 1996, European journal of immunology.
[43] P. A. Peterson,et al. CD8 enhances formation of stable T-cell receptor/MHC class I molecule complexes , 1996, Nature.
[44] Y. Chien,et al. A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. , 1996, Immunity.
[45] Partho Ghosh,et al. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2 , 1996, Nature.
[46] Antonio Lanzavecchia,et al. T Cell Activation Determined by T Cell Receptor Number and Tunable Thresholds , 1996, Science.
[47] D. Stuart,et al. Crystal structure of the complex between human CD8alpha(alpha) and HLA-A2. , 1997, Nature.
[48] D. Stuart,et al. Crystal structure of the complex between human CD8αα and HLA-A2 , 1997, Nature.
[49] Y. Chien,et al. CD4 augments the response of a T cell to agonist but not to antagonist ligands. , 1997, Immunity.
[50] J. Cerottini,et al. Effects of Epitope Modification on T Cell Receptor–Ligand Binding and Antigen Recognition by Seven H-2Kd–restricted Cytotoxic T Lymphocyte Clones Specific for a Photoreactive Peptide Derivative , 1997, The Journal of experimental medicine.
[51] R. Phillips,et al. Antagonism of cytotoxic T lymphocyte‐mediated lysis by natural HIV‐1 altered peptide ligands requires simultaneous presentation of agonist and antagonist peptides , 1997, European journal of immunology.
[52] T. Preckel,et al. Altered Hapten Ligands Antagonize Trinitrophenyl-specific Cytotoxic T Cells and Block Internalization of Hapten-specific Receptors , 1997, The Journal of experimental medicine.
[53] P. Klenerman,et al. The influence of antigenic variation on cytotoxic T lymphocyte responses in HIV-1 infection , 1998, Journal of Molecular Medicine.
[54] S. Rowland-Jones,et al. Antigen-specific release of beta-chemokines by anti-HIV-1 cytotoxic T lymphocytes. , 1998, Current biology : CB.
[55] S. Rowland-Jones,et al. Antigen–specific release of β-chemokines by anti-HIV-1 cytotoxic T lymphocytes , 1998, Current Biology.
[56] J. Altman,et al. Initiation of signal transduction through the T cell receptor requires the multivalent engagement of peptide/MHC ligands [corrected]. , 1998, Immunity.
[57] R. Korngold,et al. A structure-based approach to designing synthetic CD8α peptides that can inhibit cytotoxic T-lymphocyte responses , 1998, Nature Medicine.
[58] Mark M. Davis,et al. LIGAND RECOGNITION BY T CELL RECEPTORS , 1998 .
[59] P. Klenerman,et al. Copresentation of natural HIV-1 agonist and antagonist ligands fails to induce the T cell receptor signaling cascade. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[60] P. Allen,et al. Fidelity of T cell activation through multistep T cell receptor zeta phosphorylation. , 1998, Science.
[61] Z Reich,et al. Ligand recognition by alpha beta T cell receptors. , 1998, Annual review of immunology.
[62] B K Jakobsen,et al. T cell receptor and coreceptor CD8 alphaalpha bind peptide-MHC independently and with distinct kinetics. , 1999, Immunity.